Literature DB >> 34080892

Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.

Afagh Garjani1, Rachael Hunter2, Graham R Law3, Rodden M Middleton4, Katherine A Tuite-Dalton4, Ruth Dobson5, David V Ford4, Stella Hughes6, Owen R Pearson7, David Rog8, Emma C Tallantyre9, Richard Nicholas10, Richard Morriss11, Nikos Evangelou1, Roshan das Nair11.   

Abstract

BACKGROUND: People with MS (pwMS) have had higher rates of anxiety and depression than the general population before the COVID-19 pandemic, placing them at higher risk of experiencing poor psychological wellbeing during the pandemic.
OBJECTIVE: To assess mental health and its social/lifestyle determinants in pwMS during the first wave of the outbreak in the United Kingdom.
METHODS: This is a community-based, prospective longitudinal cohort and cross-sectional case-control online questionnaire study. It includes 2010 pwMS from the UK MS Register and 380 people without MS.
RESULTS: The Hospital Anxiety and Depression Scale scores of pwMS for anxiety and depression during the outbreak did not change from the previous year. PwMS were more likely to have anxiety (using General Anxiety Disorder-7) and/or depression (using Patient Health Questionnaire-9) than controls during the outbreak (OR: 2.14, 95% CI: 1.58-2.91). PwMS felt lonelier (OR: 1.37, 95% CI: 1.04-1.80) reported worse social support (OR: 1.90, 95% CI: 1.18-3.07) and reported worsened exercise habits (OR: 1.65, 95% CI: 1.18-2.32) during the outbreak than controls.
CONCLUSION: Early in the pandemic, pwMS remained at higher risk of experiencing anxiety and depression than the general population. It is important that multidisciplinary teams improve their support for the wellbeing of pwMS, who are vulnerable to the negative effects of the pandemic on their lifestyle and social support.

Entities:  

Keywords:  COVID-19; Multiple sclerosis; lifestyle; mental health; social

Mesh:

Year:  2021        PMID: 34080892     DOI: 10.1177/13524585211020435

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  5 in total

1.  Social isolation, loneliness and mental health sequelae of the Covid-19 pandemic in Parkinson's disease.

Authors:  Bradley McDaniels; Indu Subramanian
Journal:  Int Rev Neurobiol       Date:  2022-04-23       Impact factor: 4.280

Review 2.  Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: A rapid systematic review.

Authors:  Amin Zarghami; Mohammad A Hussain; Julie A Campbell; Chigozie Ezegbe; Ingrid van der Mei; Bruce V Taylor; Suzi B Claflin
Journal:  Mult Scler Relat Disord       Date:  2022-01-25       Impact factor: 4.808

3.  A National Representative, Cross-Sectional Study by the Hellenic Academy of NeuroImmunology (HEL.A.NI.) on COVID-19 and Multiple Sclerosis: Overall Impact and Willingness Toward Vaccination.

Authors:  Marina Boziki; Charis Styliadis; Christos Bakirtzis; Eleni Grigoriadou; Aggeliki-Styliani Sintila; Ioannis Nikolaidis; Aliki Vrienniou; Lotte Geys; Sygkliti-Henrietta Pelidou; Lesley Probert; Georgios Papazisis; Panagiotis Bamidis; Nikolaos Grigoriadis
Journal:  Front Neurol       Date:  2021-11-25       Impact factor: 4.003

Review 4.  Telemedicine as a strategic intervention for cognitive rehabilitation in MS patients during COVID-19.

Authors:  Fereshteh Ghadiri; Abdorreza Naser Moghadasi; Mohammad Ali Sahraian
Journal:  Acta Neurol Belg       Date:  2022-01-30       Impact factor: 2.471

5.  The impact of the COVID-19 pandemic on physical therapy practice for people with multiple sclerosis: A multicenter survey study of the RIMS network.

Authors:  Turhan Kahraman; Kamila Rasova; Johanna Jonsdottir; Carme Santoyo Medina; Daphne Kos; Susan Coote; Andrea Tacchino; Tori Smedal; Ellen Christin Arntzen; Gillian Quinn; Yvonne Learmonth; Ludovico Pedulla; Lousin Moumdjian; Alon Kalron
Journal:  Mult Scler Relat Disord       Date:  2022-04-10       Impact factor: 4.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.